As appropriate to individual experiments, a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, and/or a nuclear factor-B (NF-B) inhibitor, BAY11-7082, were added 1 h prior to IGF-1 treatment
Disclosure of interest: Diego Torres Nuez: nothing to disclose, Maria Esther Llorente Iniesta: nothing to disclose, Ramon Miano Monedero: nothing to disclose, Francisco Martinez Garcia: nothing to disclose, Angel Valero Lopez: nothing to disclose, Carmen Maria Sanchez Garcia: nothing to disclose, Pedro Lucas Arnaldos Illan: nothing to disclose, Maria Obdulia Lozano Caballero: nothing to disclose, Laura Albert Lacal: nothing to disclose, Ainara Sanz Monllor: nothing to disclose, Estefania Garcia Molina: nothing to disclose, Cesar Lucas Rodenas: nothing to disclose, Maria Dolores Espinosa Garcia: nothing to disclose, Eduardo Pinar Bermudez: nothing to disclose, Ana Morales: nothing to disclose E-Posters - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.04 - RARE CAUSES INCL
Human Reproduction , 18(6), 1334-1342
CJC-1295 + Ipamorelin Research Applications GHRH-R and GHS-R1a co-activation studies on pituitary somatotrophs
& Tadvi, N
